NCT06333587 Minimally Invasive Treatments of the Thyroid
| NCT ID | NCT06333587 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Papillary Thyroid Microcarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 270 participants |
| Start Date | 2022-10-10 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 270 participants in total. It began in 2022-10-10 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)
Eligibility Criteria
Inclusion Criteria: * Patients \> 18years * Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up Exclusion Criteria: * Tumors \> 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study
Contact & Investigator
Giovanni Mauri
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT06333587 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Papillary Thyroid Microcarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06333587 currently recruiting?
Yes, NCT06333587 is actively recruiting participants. Contact the research team at giovanni.mauri@ieo.it for enrollment information.
Where is the NCT06333587 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06333587 clinical trial?
NCT06333587 is sponsored by European Institute of Oncology. The principal investigator is Giovanni Mauri at European Institute of Oncology. The trial plans to enroll 270 participants.